Trial · NCT01600573
Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)
NCT01600573, Phase 1, Phase 2, Unknown, JSehouli
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ). Trials, record NCT01600573. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01600573
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)
- NCT number
- NCT01600573
- Status
- Unknown
- Phases
- Phase 1, Phase 2
- Enrollment
- 68 participants, estimated
- Lead sponsor
- JSehouli
- Conditions
- Ovarian Cancer
- Interventions
- pazopanib in combination with weekly topotecan
- First posted
- 2012-05-17
- Last updated
- 2016-10-11
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Phase I: Assessment of dose-limiting toxicity in order to determine the maximum tolerated dose (MTD) of pazopanib in combination with weekly topotecan | after 4 weeks | Dose-limiting toxicities are defined as follows: * grade 3 or 4 non-hematologic toxicity other than nausea or vomiting * grade 3 or 4 thrombocytopenia (platelet count less than 50000/µl) * grade 4 neutropenia lasting ≥ 7 days or febrile neutropenia defined as ANC \<1000/µl concurrent with fever * Any grade 2 and more toxicity of cycle 1 other than nausea, vomiting, rash, alopecia or anemia, that persisted over 35 days. |
| Primary | • Phase II: Progression-free survival according to RECIST criteria | up to 3.5 years | • Phase II: Progression-free survival according to RECIST criteria |
| Secondary | • Overall survival | up to 3.5 years | • Overall survival |
| Secondary | • Response rate (CR, PR) according to RECIST criteria | up to 3.5 years | • Response rate (CR, PR) according to RECIST criteria |
| Secondary | • Clinical benefit rate (CR, PR, SD) | up to 3.5 years | • Clinical benefit rate (CR, PR, SD) |
| Secondary | • Duration of response | up to 3.5 years | • Duration of response |
| Secondary | • Time to progression (TTP) | up to 3.5 years | • Time to progression (TTP) |
| Secondary | • Evaluation of CA-125 tumour response | up to 3.5 years | • Evaluation of CA-125 tumour response |
| Secondary | Safety and tolerability of pazopanib in combination with weekly topotecan | up to 3.5 years | Incidence and type of AE in terms of: * All AE, * Related AE, * SAE, * Related SAE, * NCI-CTC (version 4.0) grade 3 and 4 AE, * Related NCI-CTC (version 4.0) grade 3 and 4 AE, * AE leading to treatment discontinuation, * Incidence of, and reason for, deaths. |
| Secondary | • Quality of life as defined by EORTC-QLQ C 30 and Ovar 28 questionnaire | up to 3.5 years | • Quality of life as defined by EORTC-QLQ C 30 and Ovar 28 questionnaire |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 37000264 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01600573
GET https://conductscience.org/api/trials/v1/NCT01600573/registered